1. Home
  2. PCT vs COAG Comparison

PCT vs COAG Comparison

Compare PCT & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PureCycle Technologies Inc.

PCT

PureCycle Technologies Inc.

HOLD

Current Price

$6.08

Market Cap

1.3B

Sector

Utilities

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$39.22

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCT
COAG
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
PCT
COAG
Price
$6.08
$39.22
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
3.1M
286.6K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
30.86
N/A
EPS
N/A
N/A
Revenue
$8,355,000.00
N/A
Revenue This Year
$380.44
N/A
Revenue Next Year
$203.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$27.47
52 Week High
$15.49
$55.42

Technical Indicators

Market Signals
Indicator
PCT
COAG
Relative Strength Index (RSI) 32.81 34.71
Support Level $5.75 $28.51
Resistance Level $6.23 $53.01
Average True Range (ATR) 0.33 3.60
MACD -0.05 -0.98
Stochastic Oscillator 3.57 0.31

Price Performance

Historical Comparison
PCT
COAG

About PCT PureCycle Technologies Inc.

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: